Project Three: Assessing effects of anti-CD52g Mabs on STD pathogens in semen

项目3的目标是确定人类避孕抗体（HCA）是否与 中和精液中的性病病原体这些实验背后的基本原理是我们的观察 男性生殖道限制性抗原CD 52 g是HCA的靶点。插入孔 GPI锚入精液中白细胞和寄生虫的质膜。我们假设 HCA将结合并中和精液中的HIV感染细胞，以及包膜病毒， 从男性生殖道中感染的CD 52 g包被细胞中提取CD 52 g。结果进行 研究将证明HCA是否具有作为避孕药和STI的双重活性 杀菌剂 我们的具体目标是： 1.确定CD 52 g是否附着于精液白细胞、STI病毒（HIV-1、HSV-2和 ZIKV）和阴道毛滴虫。 2.确定HCA是否与HIV感染的精液白细胞、STI病毒和 阴道毛滴虫并抑制它们感染靶细胞的能力。 3.确定精液白细胞、病毒和寄生虫是否被CD 52 g包被 用HCA处理后相互凝集或与精子凝集。 4.确定HCA和HCA的工程变体是否捕获CD 52 g包被的白细胞，STI 宫颈粘液中的病毒和寄生虫（与项目2合作）

The goal of Project 3 is to determine whether Human Contraception Antibody (HCA) binds to and neutralizes STI pathogens in semen. The rationale behind these experiments is our observation that the male reproductive tract restricted antigen CD52g, which is the target of HCA. inserts via GPI anchor into the plasma membrane of leukocytes and parasites in semen. We hypothesize that HCA will bind to and neutralize HIV infected cells in semen, as well as enveloped viruses that pick up CD52g from infected CD52g-coated cells in the male genital tract. Results of these studies will demonstrate whether HCA has dual activity as a contraceptive agent and STI microbicide. Our Specific Aims are: 1. Determine whether CD52g attaches to seminal leukocytes, STI viruses (HIV-1, HSV-2 and ZIKV) and Trichomonas vaginalis. 2. Determine whether HCA binds to HIV-infected seminal leukocytes, STI viruses and Trichomonas vaginalis. and inhibits their ability to infect target cells. 3. Determine whether seminal leukocytes, viruses and parasites that are coated with CD52g agglutinate with each other or with sperm after treatment with HCA. 4. Determine whether HCA and engineered variants of HCA trap CD52g-coated leukocytes, STI viruses and parasites in cervical mucus (collaboration with Project 2)